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Abstract Ligand activation of peroxisome proliferator-acti-
vated receptor Q (PPARQ) has been reported to induce growth
inhibition and apoptosis in various cancers including hepatocel-
lular carcinoma (HCC). However, the e¡ect of hepatitis B virus
X protein (HBx) on PPARQ activation has not been character-
ized in hepatitis B virus (HBV)-associated HCC. Herein, we
demonstrated that HBx counteracted growth inhibition caused
by PPARQ ligand in HBx-associated HCC cells. We found that
HBx bound to DNA binding domain of PPARQ and HBx/PPARQ
interaction blocked nuclear localization and binding to recogni-
tion site of PPARQ. HBx signi¢cantly suppressed a PPARQ-
mediated transactivation. These results suggest that HBx mod-
ulates PPARQ function through protein^protein interaction.
/ 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Peroxisome proliferator-activated receptor Q (PPARQ) be-
longs to the steroid hormone receptor superfamily and regu-
lates cell growth, di¡erentiation, insulin sensitization, and glu-
cose homeostasis [1]. Upon receptor ligation, PPARQ forms
heterodimers with the retinoid X receptor (RXR) [2], which
bind to speci¢c DNA regions, called peroxisome proliferator
response elements (PPRE), in the 5P £anking region of target
genes [3], and form complexes with coactivators and corepres-
sors involved in PPAR/RXR-mediated transactivation [1].
Recently, it has been reported that the ligand-induced acti-
vation of PPARQ shows anti-tumor e¡ect by inducing growth
inhibition, terminal di¡erentiation, and apoptosis in various
human cancer cells, including colon, prostate and breast can-
cer, and liposarcoma [4^8]. It was also reported that the
ligand activation of PPARQ induced growth inhibition and
apoptosis in hepatocellular carcinoma (HCC) cells [9^11],
however, its e¡ect on virus-associated HCC has not been
clari¢ed.
Hepatitis B virus (HBV) is considered to be the major cause
of hepatitis, cirrhosis, and HCC. Among the HBV proteins,
hepatitis B virus X protein (HBx) is considered to contribute
signi¢cantly to the mediation of pathological events and to
the dysregulation of gene expression through protein^protein
interactions with endogenous cellular proteins and transcrip-
tional factors. The transactivatory role of HBx is thought to
be mediated by its interaction with transcription factors, such
as RPB5 of RNA polymerase [12], TATA binding protein
[13], transcription factor IIB [14], bZIP protein [15], and
RXR [16]. It has been also reported that HBx interferes
with p53 by direct binding and by sequestering p53 in the
cytoplasm, leading to the abrogation of p53-mediated cellular
processes [17^19]. Wang et al. [20] reported that HBx inhibits
sequence-speci¢c DNA binding and thus blocks the transcrip-
tional activity of p53. HBx is known to promote cellular
transformation, as demonstrated by the immortalization of
primary mouse hepatocytes [21] and by the development of
hepatoma in HBx transgenic (HBx-TG) mice [22^24]. HBx is
involved in the activation of signal transduction pathways,
such as Ras-Raf-MAP kinase, PI3 kinase, protein kinase C,
Src kinase, nuclear factor (NF)-UB, and Jak1-STAT signal
pathways, which lead to the activation and regulation of var-
ious genes that contribute to cellular proliferation and carci-
nogenesis [25].
In this study, we examined the e¡ect of HBx on the growth
inhibition induced by PPARQ ligand in HCC cells. We also
described that HBx bound to PPARQ and HBx/PPARQ inter-
action in the cytoplasm, and that this interfered with the nu-
clear localization and DNA binding of PPARQ, leading to the
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suppression of the transcriptional activity of PPARQ. Thus,
our data show a novel association between HBx and PPARQ,
which may provide another important mechanism in the
pathogenesis of HBV-associated HCC.
2. Materials and methods
2.1. Cell lines and culture
Chang liver (ATCC CCL-13), HepG2 (ATCC HB-8065) and
HEK293 (ATCC CRL-1573) were obtained from the American
Type Tissue Culture Collection (Manassas, VA, USA). Chang,
HEK293, HepG2 and HepG2.2.15 cells [26] were maintained in modi-
¢ed Eagle’s medium (MEM) supplemented with 10% fetal bovine
serum (FBS). Chang X-34 cells are Chang liver cells expressing HBx
under the control of tetracycline inducible promoter [19]. HBx was
induced with 2 Wg/ml doxycycline (Sigma, St. Louis, MO, USA) in
Chang X-34 cells.
2.2. Plasmids and plasmid construction
A series of green £uorescent protein (GFP)^PPARQ fusion con-
structs (pEGFP-PPARQ F, D, DL, L) shown in Fig. 2B were gener-
ated by polymerase chain reaction (PCR) ampli¢cation of the PPARQ
gene with speci¢c primer sets, corresponding to the PPARQ full length
(F; residues 1^475), PPARQ DNA binding domain (DBD) (D; resi-
dues 94^181), PPARQ DNA and ligand binding domain (LBD) (DL;
residues 94^475), and PPARQ LBD (L; residues 281^475). These were
then subcloned into the SacI^SalI site of pEGFP vector (Clontech,
Palo Alto, CA, USA). To generate His fusion recombinant HBx
(rHBx) protein, an ampli¢ed HBx fragment was cloned into EcoRI^
HindIII sites of pRSET A (Invitrogen, Carlsbad, CA, USA). PPRE3-
thymidine kinase (tk)-LUC and pCMX-PPARQ [27] were kindly pro-
vided by Dr. R. Evans. The HBx DNA construct, pSVX, and its
frameshift mutant, pSVXUB [28], were used for the transfection ex-
periments. To express HBx with a hemagglutinin (HA) epitope tag at
the N-terminal (pCMV-HA^HBx), the HBx fragment was ampli¢ed
by PCR and subcloned into the EcoRI^KpnI site of pCMV-HA plas-
mid (Invitrogen).
2.3. Generation and infection of recombinant adenoviruses
The construction of adenoviral vectors was performed as described
previously [29]. The adenoviral plasmids (pAdEasy-1, -2) and the
shuttle vectors (pShuttle, pShuttle-CMV, pAdTrack, and pAdTrack-
CMV) were constructed by subcloning the PCR product of HBx.
Approximately 3U106 HEK293 cells were plated in 25 cm2 £asks
24 h before transfection, by which time they had reached 50^70%
con£uency. 4 Wg of recombinant adenoviral vector DNA, digested
with PacI, was then transfected using 20 Wl LipofectAMINE (Gibco
BRL). The transfected cells were monitored for GFP expression and
harvested 7 days after transfection. Cells were collected and lysed by
three cycles of freezing/thawing. A concentrated adenovirus fraction
was prepared by CsCl gradient centrifugation and stored with 2U
storage bu¡er (10 mM Tris, pH 8.0, 100 mM NaCl, and 0.1% bovine
serum albumin (BSA), and 50% glycerol) at 320‡C. 1 Wl of virus stock
was used to infect 3^5U106 cells. The e⁄ciencies of the infections
were monitored by GFP expression.
2.4. rHBx protein expression
His fusion rHBx protein was expressed in Escherichia coli strain
BL21(DE3) and puri¢ed on nickel agarose bead. Protein expression,
preparation of inclusion body protein, and refolding of denatured
protein were performed as described previously [30].
2.5. HBx-TG mice
HBx-TG mice were generated [24] and maintained as described
previously [31]. We used HBx homozygote transgenic mice and age-
matched wild-type controls. The protocol for mice maintenance was
approved by the Committee for the Care and Use of Laboratory
Animals at Yonsei University, according to the Guide for Animal
Experiments edited by the Korean Academy for Medical Association.
2.6. Antibodies and reagents
Antibodies against PPARQ (sc-7273), HA (sc-805, sc-7392), and
GFP (sc-9996, sc-8334) were from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Antiserum against HBx was prepared by intraper-
itoneal immunization to BALB/c mice with rHBx emulsi¢ed with
complete and sequentially incomplete Freund’s adjuvant and its reac-
tivity was screened by Western blot and enzyme-linked immunosor-
bent assay (ELISA). The antibodies against K-tubulin and histone
were from Oncogene (Darmstadt, Germany) and Chemicon Inter-
national Inc. (Temecula, CA, USA), respectively. Protein G/A was
purchased from Gibco, and protein assay reagent and enhanced
chemiluminescence reagent were from Pierce (Rockford, IL, USA).
Troglitazone, provided by SanKyo (Tokyo, Japan), was prepared as
previously described [32].
2.7. Cell proliferation assay
Cell growth was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyl tetrazolium bromide (MTT) assay [33]. Brie£y, 1U103 cells were
seeded into 96-well plates and treated with troglitazone and incubated
for di¡erent time periods. After treatment, 50 Wl MTT solution (1 mg/
ml in phosphate-bu¡ered saline (PBS)) was added to each well, and
incubated for 4 h at 37‡C. The plate was then centrifuged at 3000 rpm
for 10 min, the supernatant was discarded, and the remaining adhered
cells were dissolved in 50 Wl dimethyl sulfoxide (DMSO) (Sigma). The
optical density (OD) of each well was measured at 570 nm using an
ELISA reader.
2.8. Reverse transcriptase (RT)-PCR
Total RNA was prepared using RNeasy Kit (Qiagen Inc, Chats-
worth, CA, USA). Reverse transcription for cDNA was performed
from 5 Wg total RNA using 2 Wg random hexamer (Amersham Phar-
macia Biotech Inc., Uppsala, Sweden), 1.25 mM deoxyribonucleoside
triphosphate (dNTP) (Boehringer-Mannheim, Mannheim, Germany)
and with or without addition of 200 U M-MLV RT (Gibco BRL).
PCR was performed using 0.25 mM dNTP, 0.25 U Taq polymerase
(Perkin Elmer, Norwalk, CT, USA), 10 pmol primer pair and 3 Wl
cDNA with a thermal cycler. The primer sequences were as follows:
HBx, 5P-CGGAATTCCGATGGCTGCTAGGAT-3P (sense) and 5P-
CGGGGTACCCCGT-TAGGCAGAGGT-3P (antisense); L-actin, 5P-
TTGTAACCAACTGGGACGATTGG-3P (sense) and 5P-GATCTT-
GATCTTCATGG-TGCTAGG-3P (antisense). PCR cycling condi-
tions were as follows: denaturation at 92‡C for 30 s, annealing at
55‡C for 30 s, and extension at 72‡C for 1 min.
2.9. Immunoprecipitation and Western blot analysis
For the HBx and PPARQ co-immunoprecipitation assay, Chang X-
34 cells were treated with 2 Wg/ml doxycycline, and then lysed with
radioimmunoprecipitation assay (RIPA) bu¡er containing 50 mM
Tris^Cl, pH 7.4, 100 mM NaCl, 0.5 mM ethylenediamine tetraacetic
acid (EDTA), 0.2% NP-40 and 2 mM MgCl2 supplemented with
protease inhibitor cocktail (Sigma). To detect the intracellular inter-
actions of HBx with the deletion mutants of PPARQ, HEK293 cells
were cotransfected with pCMV-HA^HBx and pEGFP-PPARQ F, D,
DL, or L, respectively. Cell lysates (500 Wg) were then incubated with
1 Wg anti-HA monoclonal antibody and incubated with protein G/A,
and Western blotting was performed using polyclonal anti-HA, anti-
PPARQ, and anti-GFP antibodies. To detect the HBx and PPARQ
protein expression in the mouse liver tissues, tissues were fractionated
into cytosolic, and nuclear extracts [32] and analyzed by quantitative
Western blot analysis using HBx antiserum and anti-PPARQ antibody.
2.10. Immuno£uorescence assay (IFA)
IFA was used to investigate subcellular localization of the HBx and
PPARQ. Brie£y, Chang liver cells were seeded into Lab-Tek two-
chamber glass slides (Nalge Nunc, Naperville, IL, USA) and transi-
ently transfected with pEGFP-PPARQ and pCMV-HA^HBx. Cells
were incubated with 20 WM troglitazone for 24 h, washed and ¢xed
with 4% paraformaldehyde in PBS and permeabilized with 0.1% sap-
onin (Sigma) in PBS. Cells were then incubated with anti-HA anti-
body and then with Cy3-conjugated IgG (Zymed Laboratories Inc.,
San Francisco, CA, USA). After several washes, cells were mounted
using mounting medium containing 4,6-diamino-2-phenylindole
(DAPI) (Vector Laboratories, Burlingame, CA, USA) and visualized
under a confocal microscope, LSM 510 (Carl Zeiss, Jena, Germany),
or £uorescence microscope (Olympus America Inc., Melville, NY,
USA) with MetaMorph software (Universal Imaging Corporation,
Downingtown, PA, USA).
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2.11. Electrophoretic mobility shift assay (EMSA)
Preparations of nuclear extract (NE) and EMSA were carried out
as previously described [32]. For the binding reaction, 5 Wg NE was
incubated with the 32P-labeled probe in binding bu¡er containing 10
mM Tris, pH 7.5, 100 mM KCl, 1 mM dithiothreitol (DTT), 1 mM
EDTA, 0.2 mM phenylmethylsulfonyl £uoride (PMSF), 1 mg/ml
BSA, and 5% glycerol at room temperature for 30 min. For the
competition experiments, a 100 molar excess cold probe was added
to the reaction mixture. To examine the e¡ect of HBx on the DNA
binding activity of PPARQ, rHBx was added to the reaction mixture
for 30 min, and then the probes were added. For SP-1 binding, 2 Wg
NE was incubated with the labeled probe. The sequence of the oligo-
nucleotides used as probes was as follows: CYP4A-PPRE, 5P-TG-
AAACTAGGGTAAAGTTCA-3P ; SP-1, 5P-GATCGATCGGGGC-
GGGGCGAG-3P.
2.12. Luciferase reporter assay
Chang liver cells (2U105) were seeded onto 12-well culture plates
and transfection was carried out using LipofectAMINE (Gibco BRL),
according to the manufacturer’s instruction. The total amount of
DNA was adjusted to 1 Wg; 500 ng PPRE3-tk-LUC, 200 ng
pCMX-PPARQ, 200 ng pSVX or pSVXUB, 100 ng pCMV-L-gal,
Fig. 1. HBx abolishes the inhibitory e¡ect of troglitazone on cellular proliferation. A: HepG2 (left panel) and HepG2.2.15 (right panel) cells
were treated with 1.0^20 WM troglitazone for the indicated times, and cell proliferation was determined by MTT assays. B: (a) HepG2 cells
transduced with recombinant adenovirus carrying HBx (Ad-GFP^HBx) or control virus (Ad-GFP) were treated with 20 WM troglitazone for
the indicated times and cell proliferation was determined by MTT assays. Results are represented as relative OD compared with the control
and normalized values are shown as meansUS.D. Assays were performed at least three times using quadruplicate samples, and the data of a
representative experiment are shown. (b) Transduction e⁄ciency of Ad-GFP and Ad-GFP^HBx into HepG2 cells. GFP microscopic ¢nding
showed that more than 95% HepG2 cells were transduced in all the ¢elds observed. (c) HBx expression after transduction of Ad-GFP^HBx.
After transduction of Ad-GFP and Ad-GFP^HBx, total RNA was extracted from transduced HepG2 cells and treated with RNase-free DNase
and then analyzed by RT-PCR with (+) or without (3) RT.
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and empty vectors. After 3 h of transfection, the cells were washed
and incubated in a complete medium containing 20 WM troglitazone
for 24 h. Cells were then washed and lysed using 1U lysis bu¡er
(Promega, Madison, WI, USA). Lysates were measured for luciferase
activity using luciferin (Promega), and L-galactosidase activity was
measured as an internal control.
3. Results
3.1. HBx suppresses PPARQ-induced growth inhibition in HCC
cells
HepG2 cells express PPARQ, and their growth is inhibited
by troglitazone [10,11]. However, in this study, we found that
HepG2.2.15 cells, which had been established by transfecting
four tandem copies of the HBV genome into HepG2 cells [26],
were resistant to troglitazone. When cells were treated with
troglitazone for di¡erent times, the proliferation of HepG2
cells signi¢cantly decreased in a dose-dependent manner.
However, HepG2.2.15 cells appeared to be more resistant to
troglitazone-induced growth inhibition than HepG2 cells (Fig.
1A). To exclude the possibility that the di¡erence of sensitivity
to troglitazone was due to di¡erent sublines used, we exam-
ined HepG2 infected with recombinant adenovirus carrying
HBx (HepG2-Ad-HBx). As shown in Fig. 1B, the growth
rate of HepG2-Ad-HBx cells was signi¢cantly higher than
that of HepG2 cells infected with Ad-GFP empty vector.
Thus, these results demonstrate that HBx signi¢cantly sup-
pressed troglitazone-induced growth inhibition in HCC cells.
3.2. HBx binds to PPARQ in vivo
It was reported that HBx mediates its biological activity
through protein^protein interactions with transcription fac-
tors [12^16]. To determine whether HBx interacts with PPARQ,
an immunoprecipitation assay was performed. Chang X-34
cells, which express HBx-HA under the control of tetracycline
inducible promoter, were incubated with doxycycline for var-
ious times. Cell lysates were immunoprecipitated with an anti-
HA monoclonal antibody, and then analyzed using an anti-
PPARQ antibody. The HBx^PPARQ complex was found to
increase in proportion to the amount of HBx expressed by
doxycycline, in a time-dependent manner, although the endog-
enous PPARQ protein level was una¡ected by HBx (Fig. 2A).
To determine which domain of PPARQ is involved in this
binding, HEK293 cells were transfected with pCMV-HA^
HBx and a series of GFP^PPARQ fusion constructs (Fig.
2B). Cell lysates were then immunoprecipitated with an anti-
HA antibody, and analyzed with an anti-GFP antibody. As
shown in Fig. 2C, upper panel, PPARQ F, D and DL were
found to be associated with HBx. This ¢nding demonstrates
that HBx binds to PPARQ, and that the DBD^hinge region of
PPARQ is critical for HBx binding, because GFP^PPARQ D is
composed of DBD and hinge region.
3.3. HBx interferes with the nuclear localization of PPARQ
DBD of PPARQ is involved in the binding to PPRE, and
the hinge region participates in nuclear localization and the
formation of heterodimers [34,35]. Having observed that HBx
binds to the DBD^hinge region of PPARQ, we investigated
whether the HBx^PPARQ interaction a¡ects the nuclear local-
ization of PPARQ. Chang liver cells were cotransfected with
pEGFP-PPARQ and pCMV-HA^HBx, and IFA was then per-
formed. In the absence of HBx, PPARQ was found to be
localized mainly in the nucleus, regardless of troglitazone
treatment (Fig. 3A, upper panel). However, in the presence
of HBx the localization of PPARQ changed from the nucleus
to the cytoplasm, although some PPARQ remained in the nu-
cleus (Fig. 3A, lower panel). As shown in Fig. 3B, this cyto-
plasmic PPARQ was found to be colocalized with HBx
(merged; yellow color).
Fig. 2. Interaction of PPARQ with HBx in vivo. A: After treating
Chang X-34 cells with 2 Wg/ml doxycycline, (a) the cell lysate was
immunoprecipitated with anti-HA monoclonal antibody and ana-
lyzed on 10% sodium dodecyl sulfate^polyacrylamide gel electropho-
resis (SDS^PAGE). Western blot was performed with anti-PPARQ
antibody. C, immunoprecipitation with normal mouse immunoglob-
ulin. (b) Western blot with anti-HA antibody. (c) Western blot with
anti-PPARQ, showing that an equal amount of PPARQ had been
loaded. B: A schematic diagram of four GFP^PPARQ fusion con-
structs encoding the indicated domain. C: After transfection with
the HA^HBx and GFP^PPARQ fusion constructs (PPARQ F, D,
DL, or L), HEK293 cells were lysed and the cell lysates were immu-
noprecipitated with mouse anti-HA monoclonal antibody. Western
blot was performed with rabbit anti-GFP polyclonal antibody after
immunoprecipitation (upper panel). C, immunoprecipitation with
normal mouse immunoglobulin. The same amount of cell lysates
was analyzed by Western blot with mouse anti-GFP monoclonal
antibody (lower panel).
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3.4. PPARQ expression is reduced in the nucleus of HBx-TG
mouse liver
To determine whether this interference with the nuclear
localization of PPARQ by HBx occurs in vivo, we prepared
the mouse liver tissue extracts from HBx-TG and age-matched
control C57BL/6 which were fractionated into cytosolic, and
nuclear extracts for the quanti¢cation, and then Western blot
was performed using anti-PPARQ antibody and HBx antise-
rum. Both proteins were detected in total and cytosolic com-
partments of HBx-TG. No signi¢cant di¡erence was found in
the PPARQ expression in the total and cytosolic compartments
between the HBx-TG and control C57BL/6 mouse liver tis-
sues, however the expression of PPARQ in the nuclear extracts
of the HBx-TG was signi¢cantly lower than in that of the
control (Fig. 4).
3.5. The DNA binding of PPARQ is reduced in HBx-TG mouse
liver
To determine whether reduced PPARQ expression in the
nucleus of HBx-TG mouse liver is associated with the DNA
binding activity of PPARQ, EMSA was performed with
PPRE. NE was prepared from the livers of 13-month-old
HBx-TG mice and age-matched C57BL/6 mice. As shown in
Fig. 5A, the NE from the control C57BL/6 mouse livers
showed signi¢cant DNA binding to PPRE, however the
DNA binding of PPARQ was completely abrogated in the
NE of HBx-TG mouse livers. Since HBx interacts with the
PPARQ DBD^hinge region, we also investigated whether HBx
inhibits the DNA binding activity of PPARQ by performing
EMSA using NE from control C57BL/6 mouse liver, which
was preincubated with rHBx protein. Fig. 5B shows that
Fig. 3. Colocalization of PPARQ with HBx. A: pEGFP-PPARQ with or without pSVX-HBx was transfected into Chang liver cells and treated
with or without 20 WM troglitazone for 20 h, cells were observed under a confocal microscope. The partial cytoplasmic sequestration of PPARQ
was observed in the presence of HBx. Upper panel, pEGFP-PPARQ transfected Chang liver cells ; lower panel, pEGFP-PPARQ and pSVX-HBx
cotransfected Chang liver cells. B: pEGFP-PPARQ was transfected into Chang liver cells with or without pCMV-HA^HBx. After incubation
with 20 WM troglitazone for 20 h, the cells were stained and analyzed under a confocal microscope. Cells were visualized with triple colors, i.e.
GFP (PPARQ), and rabbit anti-HA antibody and Cy3-conjugated anti-rabbit IgG (HBx), and DAPI (nucleus), and merged.
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rHBx signi¢cantly reduced the DNA binding activity of
PPARQ. Overall, it appears that binding of HBx to PPARQ
interferes with the nuclear localization and the DNA binding
activity of PPARQ.
3.6. HBx suppresses the transcriptional activity of PPARQ
To determine whether the interruption of PPARQ localiza-
tion by HBx in£uences the transcriptional activity of PPARQ,
a luciferase reporter assay was performed. Compared with
Chang liver cells transfected with PPRE3-tk-LUC alone, lu-
ciferase activity was found to be increased by PPARQ over-
expression, and this activity was enhanced by troglitazone.
However, luciferase activity was markedly reduced by HBx
even in the presence of troglitazone, though this suppressive
e¡ect was not observed by the HBx mutant (Fig. 6A). In
addition, this suppressive e¡ect of HBx on transcriptional
activity was dose-dependent (Fig. 6B). These results suggest
that HBx inhibits the transcriptional activity of PPARQ.
4. Discussion
PPARQ is a nuclear hormone receptor with diverse func-
tions, which are critical for maintaining cellular processes
[36]. Several studies have demonstrated that the ligands of
PPARQ may induce apoptosis and growth inhibition in
HCC cells, which suggests that PPARQ has an anti-cancer
e¡ect [9^11]. In the present study, the proliferation of trogli-
tazone-treated HepG2 cells decreased signi¢cantly in a dose-
dependent manner, which agrees with previous reports [10,11].
Interestingly, HepG2.2.15 and HepG2 cells infected with Ad-
GFP^HBx were resistant to troglitazone, suggesting that the
introduction of the HBV genome or HBx appeared to convert
troglitazone-susceptible cells to troglitazone-resistant cells.
PPARQ is composed of two zinc ¢nger motifs, nuclear local-
ization signals (NLS), a ligand binding pocket, and several
activation functions (AF) [35]. DBD has two zinc ¢nger mo-
tifs that can bind directly to DNA, and the hinge region
contains NLS. Our immunoprecipitation assay with Chang
X-34 cells demonstrated that the protein^protein interaction
occurred between HBx and the PPARQ, and this interaction
occurred through DBD^hinge region of PPARQ. Since the
DBD^hinge region participates in the interaction with HBx,
this interaction might modulate the nuclear localization and
DNA binding of PPARQ. DBD is the most highly conserved
region between other members of steroid hormone receptor
superfamily. This fact leads to the possibility that HBx may
interact with and a¡ect other PPARQ isoforms or other ste-
roid receptor members. Previously, it was reported that the
DBD of several steroid hormone receptors could interact with
DBD-associating proteins. Thioredoxin, one of the DBD-as-
sociating proteins, interacts with the DBD of glucocorticoid
receptor [37], and the small nuclear ring ¢nger protein
SNURF directly binds to the DBD of androgen receptor
[38]. In addition to these cellular proteins, viral proteins can
also modulate steroid hormone receptors by direct protein^
protein interaction. Hepatitis C virus core protein interacts
with the DBD of RXRK [39] and HBx binds to the LBD of
RXR [16]. Since PPARQ forms a complex by heterodimerizing
with RXR and binding to other coactivators or corepressors,
it is also possible that PPARQ indirectly binds to HBx through
complex formation with other components. However, the
strong dimerization of PPARQ with RXRK is mainly mediated
by the LBD of PPARQ [40], and our data show an interaction
between PPARQ and HBx via the DBD^hinge region of
PPARQ, thus it is probable that HBx interacts with PPARQ
by direct protein^protein interaction. Moreover, our native
gel shift assay of the in vitro binding of HBx to PPARQ
demonstrated a direct protein^protein interaction. To exclude
the possibility that HBx binds to PPARQ indirectly via inter-
action with RXR, we performed an in vitro binding assay
with rHBx and three His-PPARQ proteins corresponding to
PPARQ D, DL, and L. A native gel shift assay showed shifted
bands in mixtures of HBx with PPARQ D, or PPARQ DL, but
not in mixture of HBx with PPARQ L (our unpublished ob-
servation). These results indicate that HBx binds directly to
the DBD^hinge region of PPARQ, which plays important roles
Fig. 4. Reduced PPARQ protein level in the nucleus of HBx-TG
mouse liver. Total (T: 100 Wg), cytosol (C: 100 Wg) and nuclear (N:
25 Wg) extracts were analyzed using anti-PPARQ antibody and anti-
serum against HBx. Western blotting with anti-K-tubulin and anti-
histone antibodies were used to con¢rm the fractionation.
Fig. 5. The lower PPRE binding of NE from HBx-TG mouse liver
tissues. A: NE (5 Wg) from control C57BL/6 and from HBx-TG
mouse liver were analyzed by EMSA. For the competition assay, a
100 molar excess of the cold probe was added to the reaction mix-
ture. SP-1 binding was used as control. B: NE from control
C57BL/6 mouse liver was preincubated with rHBx at room tempera-
ture for 30 min before the addition of the probe.
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in both the nuclear translocation and the DNA binding of
PPARQ.
IFA data demonstrated that PPARQ was partially seques-
tered and colocalized with HBx in the cytoplasm. These re-
sults might be due to the e¡ect of HBx on DBD and NLS at
the hinge region, leading to the interruption of the nuclear
localization of PPARQ. It was observed that the amount of
nuclear PPARQ and its DNA binding activity were reduced in
the NE of HBx-TG mouse liver tissues. We also found that
HBx displayed an inhibitory e¡ect on the PPRE binding of
PPARQ. The addition of rHBx into the NE of C57BL/6 re-
duced the DNA binding activity of PPARQ, suggesting that
nuclear PPARQ cannot bind e¡ectively to DNA in the pres-
ence of HBx. Overall, our results suggest that the partial cy-
toplasmic sequestration of PPARQ by HBx may su⁄ciently
reduce the concentration of nuclear PPARQ to prevent DNA
binding.
The physiological meaning of our ¢ndings needs further
study, because the expression of HBx is largely con¢ned to
liver parenchymal cells, where the expression of PPARQ is low
and where the function of PPARQ is unclear under normal
physiologic conditions. However, our study shows that HBx
is responsible for the suppression of the growth inhibitory
e¡ect of troglitazone in HCC cells containing HBx. It is con-
ceivable that the inhibitory e¡ect of HBx on PPARQ may be
advantageous to HBx-containing hepatocytes, leading to sur-
vive the natural ligand of PPARQ. It is also possible that HBx
plays a role in biological modulation in HBV-associated dis-
eases by interacting with and suppressing PPARQ. According
to previous reports, nuclear receptors, including PPARQ, en-
hance HBV replication [41]. HBV non-responsive mutants to
PPARQ showed reduced viral replication and a lower expres-
sion level of viral antigen [42,43], however the reduced pro-
duction of viral proteins may be favorable for the virus, giving
it rise to evade the host immune system. These results imply
that the modulation of PPARQ by HBx can e¡ectively regulate
the life cycle of HBV and its replication. Therefore, our data
suggest the possibility that HBx has an immunological or bio-
logical modulatory role in HBV-associated liver diseases, by
interacting with and suppressing PPARQ.
In the present investigation, a novel interaction between
HBx and PPARQ was studied. The results obtained from
this study show that HBx suppresses the transcriptional and
proapoptotic activities of PPARQ. Recognizing the importance
of PPARQ-mediated cellular events, our results may o¡er a
mechanism involved in the pathological e¡ects of HBx.
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